This is a routine director diversification sale following RSU vesting. The dollar amount is negligible relative to market cap. No actionable signal for traders, monitor for any follow-on insider selling patterns in future Form 4 filings.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $6.18entry
- T+1 · 5mo ago +0.97%α +0.74% · $6.24
- T+5 · 5mo ago +9.87%α +9.30% · $6.79
- T+20 · 4mo ago +35.44%α +33.58% · $8.37
- T+60 · 3mo ago +36.57%α +32.57% · $8.44
Price Chart
How similar events traded
Executive Summary
Director Dawn Halkuff filed a Form 144 notice of intent to sell 20,000 shares of Xeris Biopharma common stock, with an estimated aggregate market value of $117,800. The shares were acquired via restricted stock unit vesting on June 3, 2026. This is a relatively small proposed sale relative to the company's $1.0B market cap and represents a routine diversification move by a director, not a material signal of insider concern.
Key Facts
- Director Dawn Halkuff filed Form 144 to sell 20,000 shares of XERS common stock.
- Estimated aggregate market value of the proposed sale is $117,800.
- Shares were acquired via restricted stock unit vesting on June 3, 2026.
- The sale represents approximately 0.012% of the company's $1.0B market cap.
- The filing is an advance notice of intent to sell; the sale may not be executed.
Financial Impact
Proposed sale of $117,800 in XERS common stock by a director, immaterial relative to $1.0B market cap.
Risk Factors
- If the sale is executed, it could be followed by additional insider sales, though the current amount is too small to be concerning.
- No other material risks identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005664 |
| Document: 0001950047-26-005664-index.html | 0001950047-26-005664 |
| Document: 0001950047-26-005664.txt | 0001950047-26-005664 |
Track record
25 reports on XERS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers